Knockout of VEGFR-2 downregulates TOX expression and reactivates tumor-specific exhausted CD8+ T cells, indicating the therapeutic potential of targeting the VEGF/VEGFR-2 axis [19]. The gene discussed is VEGFA; the disease is neoplasm.